Impax Laboratories Inc (IPXL)

9.25
0.05 0.54
NASDAQ : Health Care
Prev Close 9.20
Open 9.20
Day Low/High 9.10 / 9.38
52 Wk Low/High 27.62 / 50.74
Volume 593.38K
Avg Volume 1.74M
Exchange NASDAQ
Shares Outstanding 73.75M
Market Cap 660.05M
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Impax Laboratories (IPXL)

Oversold Conditions For Impax Laboratories (IPXL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

First Week of IPXL September 15th Options Trading

First Week of IPXL September 15th Options Trading

Investors in Impax Laboratories Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.

Cigna Defends Abandoning EpiPen Coverage

Cigna Defends Abandoning EpiPen Coverage

Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

GPM Reminds Investors Of The January 9 Deadline In The Class Action Lawsuit Against Impax Laboratories, Inc.

GPM Reminds Investors Of The January 9 Deadline In The Class Action Lawsuit Against Impax Laboratories, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased Impax...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Impax Laboratories, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Impax Laboratories, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Impax Laboratories, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc.

IPXL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

IPXL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Impax Laboratories, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Impax Laboratories, Inc.

On November 10, 2016, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Impax Laboratories, Inc.